UCARTCLL1

UCARTCLL1 is an allogeneic, "off-the-shelf" chimeric antigen receptor (CAR) T-cell therapy candidate developed by Cellectis. It is engineered to target C-type lectin-like molecule 1 (CLL1, also known as CLEC12A), a cell surface antigen highly expressed on leukemic stem cells and myeloid blasts in acute myeloid leukemia (AML), while being absent on healthy hematopoietic stem cells. Unlike traditional autologous CAR-T therapies, UCARTCLL1 is derived from healthy donor T-cells. It utilizes TALEN gene-editing technology to knock out the T-cell receptor alpha constant (TRAC) gene to minimize the risk of graft-versus-host disease (GvHD) and the CD52 gene to enable the use of anti-CD52 antibodies for selective lymphodepletion. The primary indication is relapsed or refractory AML.

Other names

CLL1-targeted allogeneic CAR-T cellsCLL-1-targeted allogeneic CAR-T cellsCLL 1-targeted allogeneic CAR-T cellsCLEC12A-targeted allogeneic CAR-T cellsCLEC-12A-targeted allogeneic CAR-T cellsCLEC 12A-targeted allogeneic CAR-T cells